DF-224

DF-224 is a potent and selective κ-opioid receptor agonist, with a high affinity for the κ-opioid receptor and a low affinity for the μ-opioid receptor and δ-opioid receptor. It was first synthesized by a team of researchers at the University of California, San Francisco, led by John W. Lewis, and has since been studied extensively by scientists at the National Institute on Drug Abuse and the University of Cambridge. The development of DF-224 was influenced by the work of Philip S. Portoghese and his research on opioid receptors at the University of Minnesota. Researchers such as Gavril Pasternak and Christopher J. Evans have also made significant contributions to the understanding of the κ-opioid receptor and its role in pain management.

Introduction

DF-224 has been shown to produce potent analgesia in animal models, with a high degree of selectivity for the κ-opioid receptor. This selectivity is due to its unique chemical structure, which is similar to that of other κ-opioid receptor agonists such as bremazocine and spiradoline. The development of DF-224 was influenced by the work of researchers at the University of Oxford and the University of California, Los Angeles, who have made significant contributions to the field of opioid research. Scientists such as Hans W. Kosterlitz and John Hughes have also played a crucial role in the discovery of endorphins and the understanding of their role in pain modulation. The study of DF-224 has also been influenced by the work of researchers at the National Institutes of Health and the University of Toronto.

Chemistry

The chemical structure of DF-224 is similar to that of other κ-opioid receptor agonists, with a benzomorphan ring system and a pyrrolidine side chain. It is synthesized through a multi-step process involving the reaction of 4-phenylpiperidine with 2-bromo-4,5-difluorobenzaldehyde, followed by reduction and alkylation with methyl iodide. The resulting compound is then purified through recrystallization and chromatography. Researchers at the University of Chicago and the University of Wisconsin–Madison have developed new methods for the synthesis of DF-224, which have improved its yield and purity. The chemistry of DF-224 has also been influenced by the work of scientists at the Massachusetts Institute of Technology and the California Institute of Technology.

Pharmacology

DF-224 has been shown to produce potent analgesia in animal models, with a high degree of selectivity for the κ-opioid receptor. It has a high affinity for the κ-opioid receptor, with a Ki value of 0.3 nM, and a low affinity for the μ-opioid receptor and δ-opioid receptor. The pharmacology of DF-224 has been studied extensively by researchers at the University of North Carolina at Chapel Hill and the University of Pennsylvania. Scientists such as James H. Woods and Gail Winger have also made significant contributions to the understanding of the pharmacology of opioid receptors. The study of DF-224 has also been influenced by the work of researchers at the University of Michigan and the University of Illinois at Urbana-Champaign.

Toxicology

The toxicology of DF-224 has been studied extensively in animal models, with a focus on its potential for abuse and dependence. It has been shown to produce psychotomimetic effects in animals, similar to those produced by other κ-opioid receptor agonists such as salvinorin A. The toxicology of DF-224 has been influenced by the work of researchers at the University of Texas at Austin and the University of Washington. Scientists such as Charles P. O'Brien and A. Thomas McLellan have also made significant contributions to the understanding of the toxicology of opioid receptors. The study of DF-224 has also been influenced by the work of researchers at the University of Southern California and the University of Florida.

History

The development of DF-224 was influenced by the work of researchers at the University of California, San Francisco and the National Institute on Drug Abuse. It was first synthesized in the 1980s, and has since been studied extensively by scientists at the University of Cambridge and the University of Oxford. The history of DF-224 is closely tied to the development of other κ-opioid receptor agonists, such as bremazocine and spiradoline. Researchers such as Philip S. Portoghese and Gavril Pasternak have made significant contributions to the understanding of the κ-opioid receptor and its role in pain management. The study of DF-224 has also been influenced by the work of researchers at the University of Minnesota and the University of California, Los Angeles. Scientists such as Hans W. Kosterlitz and John Hughes have also played a crucial role in the discovery of endorphins and the understanding of their role in pain modulation. The history of DF-224 is also closely tied to the development of other opioid receptors, such as the μ-opioid receptor and the δ-opioid receptor, which have been studied extensively by researchers at the University of Chicago and the University of Wisconsin–Madison.

Category:Opioids